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Abstract: Objectives Most trials with Immune Checkpoint Inhibitors (ICIs) 
for Non-Small Cell Lung Cancer (NSCLC) included only small subgroups of 
patients aged ≥65. As NSCLC is often diagnosed  in patients aged ≥70, 
real-world data about efficacy and safety of immunotherapy (IO) in 
elderly patients are essential.  
Materials and Methods We retrospectively collected data about all 
patients with advanced NSCLC treated with IO at our Institution between 
April 2013 and March 2019. The patients were stratified for age as 
follows: <70 year-old, 70-79 year-old, ≥80 year-old. Chi-square test was 
used to compare qualitative variables. Survival was estimated with 
Kaplan-Meier method. Log-rank test was used to compare curves. 
Multivariate analyses were performed with Cox model.  
Results We reviewed 290 cases, with a median age of 67 (range: 29-89). 
Patients aged<70, 70-79 and ≥80 year-old were 180, 94 and 16, 
respectively. Clinical/pathological variables were uniformly distributed 
across age classes, except for a higher rate of males (p 0.0228) and 
squamous histology (p 0.0071) in the intermediate class. Response Rate 
(RR) was similar across age groups (p 0.9470). Median Progression Free 
Survival (PFS) and Overall Survival (OS) did not differ according to age 
(p 0.2020 and 0.9144, respectively). Toxicity was comparable across 
subgroups (p 0.6493). The only variables influencing outcome were 
performance status (PS) (p<0.0001 for PFS, p 0.0192 for OS), number of 
metastatic sites (p 0.0842 for PFS, p 0.0235 for OS) and IO line 
(p<0.0001 for both PFS and OS).  
Conclusion Advanced age was not associated to a reduced efficacy of IO in 
our case series. Furthermore, no toxicity concern emerged even among the 
eldest pts. To our opinion, ICIs should be considered irrespective of 
age, provided an optimal PS at baseline. Of note, IO is often the only 
therapeutic option applicable to these cases considering the toxicity of 
chemotherapy. 
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This is a short report about the performance of immunotherapy in our case series of elderly patients with 
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that performance status, instead of age, has a strong predictive and prognostic role during immunotherapy 
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Dear “Lung Cancer” Editorial Office,  
Dear Reviewer, 
 
Thank you for your comments. 
We modified the text of the manuscript LUNGCANCER-D-19-00747 according to your observations as 
follows: 
 
# Reviewer 1: 
1) “I just want to outline the last sentence of the conclusion: <<Of note, IO is often the only therapeutic 
option applicable to these cases considering the toxicity of chemotherapy>>. I don't think that we 
can conclude that at the end of this study. The authors should limit their conclusion to the fact that 
IO should be considered irrespective of age, provided an optimal PS at baseline.”  
Author’s response: We agree with this comment. We eliminated the sentence from the revised 
manuscript. 
REFERENCE IN THE TEXT  page 7, lines 164-167. 
2) “This is the same comment page 5 for this sentence: <<Furthermore, the general fair tolerability of 
IO renders this treatment option a chance for elderly people, who are often unsuited for 
chemotherapy due to frailty and comorbidities>>. It is not demonstrated that IO is superior to 
chemo or even allow to achieve a benefit in a population considered as unsuited for chemo because 
of frailty and comorbidities.”  
Author’s response:  Again, we agree with this comment and amended the manuscript 
consequently. 
REFERENCE IN THE TEXT  pages 3, lines 60-61. 
3) “In the discussion, the authors should oultline the fact that patients were not geriatrically 
characterized. This is a limit of this study.Concerning the toxicities, the authors should add a 
sentence explaining that due to its retrospective aspect, perhaps that report of toxicities especilaly 
of low grades could not have been exhaustive.”  
*Detailed Response to Reviewers
 Author’s response: We added a paragraph making clear the limitation of the study, particularly 
referring to the points raised in this comment.  
REFERENCE IN THE TEXT  page 7, lines 155-161. 
 
We sincerely believe that these changes bettered our manuscript. 
We hope that the result will satisfy your requests and we make ourselves fully available to further changes. 
We precise that all the authors approved manuscript adjustments. 
 
Thanking you in advance for your consideration, 
Yours sincerely 
 
Dr. Giulia Galli 
Highlights 
 Data about immunotherapy (IO) in elderly patients with Non-Small Cell Lung Cancer (NSCLC) are 
few 
 We divided our series of NSCLC patients treated with IO as follows: <70 , 70-79, ≥80 year-old 
 We found no difference in response rate, progression free survival and overall survival   
 The incidence of moderate/severe adverse events was similar in the three subgroups 
 We confirm that IO can be a safe and effective option for elderly patients with advanced NSCLC 
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Abstract 23 
Objectives Most trials with Immune Checkpoint Inhibitors (ICIs) for Non-Small Cell Lung Cancer (NSCLC) 24 
included only small subgroups of patients aged ≥65. As NSCLC is often diagnosed  in patients aged ≥70, real-25 
world data about efficacy and safety of immunotherapy (IO) in elderly patients are essential.  26 
Materials and Methods We retrospectively collected data about all patients with advanced NSCLC treated 27 
with IO at our Institution between April 2013 and March 2019. The patients were stratified for age as 28 
follows: <70 year-old, 70-79 year-old, ≥80 year-old. Chi-square test was used to compare qualitative 29 
variables. Survival was estimated with Kaplan-Meier method. Log-rank test was used to compare curves. 30 
Multivariate analyses were performed with Cox model.  31 
Results We reviewed 290 cases, with a median age of 67 (range: 29-89). Patients aged<70, 70-79 and ≥80 32 
year-old were 180, 94 and 16, respectively. Clinical/pathological variables were uniformly distributed across 33 
age classes, except for a higher rate of males (p 0.0228) and squamous histology (p 0.0071) in the 34 
intermediate class. Response Rate (RR) was similar across age groups (p 0.9470). Median Progression Free 35 
Survival (PFS) and Overall Survival (OS) did not differ according to age (p 0.2020 and 0.9144, respectively). 36 
Toxicity was comparable across subgroups (p 0.6493). The only variables influencing outcome were 37 
performance status (PS) (p<0.0001 for PFS, p 0.0192 for OS), number of metastatic sites (p 0.0842 for PFS, p 38 
0.0235 for OS) and IO line (p<0.0001 for both PFS and OS).  39 
Conclusion Advanced age was not associated to a reduced efficacy of IO in our case series. Furthermore, no 40 
toxicity concern emerged even among the eldest pts. To our opinion, ICIs should be considered irrespective 41 
of age, provided an optimal PS at baseline. Of note, IO is often the only therapeutic option applicable to 42 
these cases considering the toxicity of chemotherapy. 43 
Keywords Non Small Cell Lung Cancer; Immunotherapy; Elderly; Efficacy; Safety 44 
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Introduction  48 
Non-Small Cell Lung Cancer (NSCLC) is the second most common malignancy worldwide and its incidence 49 
increases with age, with about half of the cases diagnosed in people aged ≥70 [1].    50 
In recent years, treatment advances have deeply changed the approach to metastatic NSCLC. In particular, 51 
several trials have proved the efficacy of immunotherapy (IO) in first and more advance lines [2]. However, 52 
despite the high incidence of NSCLC in the elderly, most trials have excluded  such patients from enrolment. 53 
Recent retrospective data and some systematic reviews have tried to fill the gap of knowledge about 54 
efficacy and safety of IO in the elderly. However,  most of them did not focus on a specific disease or 55 
included only a small subgroups of cases aged ≥80. Therefore, data are still scant in particular for NSCLC 56 
and for patients in the most advanced age class [3]. 57 
Given the progressive increase in median age of the global population, and the positive correlation 58 
between age and incidence of NSCLC, a deep comprehension of its effects in the elderly in a real-world 59 
setting is crucial.  60 
We tried to address this topic, reviewing our Institutional case series of patients with advanced or 61 
metastatic NSCLC treated with IO. 62 
Materials and Methods 63 
Data about all consecutive patients with NSCLC treated with ICIs at Istituto Nazionale dei Tumori, Milan, 64 
Italy, between April 2013 and March 2019 were collected from Institutional database. All cases with 65 
advanced NSCLC receiving at least one administration of IO were considered eligible for the analysis.  66 
Response Rate (RR) was evaluated through Response Evaluation Criteria for Solid Tumors (RECIST) 1.1. 67 
Toxicity was graded according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0. 68 
Performance Status (PS) was defined according to European Cooperative Oncology Group (ECOG) criteria. 69 
As PD-L1 status on tumor tissue was evaluated through different tests, it was considered as positive 70 
whenever expressed at ≥1% level at Institutional evaluation (with DAKO22C3 kit), or positive at central 71 
evaluation for patients enrolled in clinical trials. 72 
For the purpose of the analysis, the patients were stratified according to age at the beginning of IO into 73 
three classes: <70 year-old, 70-79 year-old, ≥80 year-old. 74 
Progression Free Survival (PFS) was calculated as the time interval between the first administration of ICI 75 
and disease progression or death for any cause, whichever came first. Overall Survival (OS) was calculated 76 
as the time interval between the first administration of ICI and death for any cause. Alive patients were 77 
right-censored at the time of last contact.  78 
Chi square or Fisher’s exact test were used to compare proportions. PFS and OS were estimated through 79 
Kaplan-Meier method. Differences between survival curves were analyzed with log-rank test. Cox 80 
proportional hazard model was applied for multivariate analysis. Statistical analyses were performed using 81 
SAS (version 9.4, SAS Institute, Cary, NC, USA). 82 
Results 83 
A total of 290 cases were identified, with a median age of 67 (range: 29-89). One hundred eighty patients 84 
were aged <70, 94 were aged 70-79, 16 were aged ≥80. In the global population there was a slight 85 
prevalence of male gender (61.7%), and most patients were current or former smoker at the beginning of 86 
IO (80.7%). Tumor histology was non-squamous in 77.6% of cases. PD-L1 was classified as positive in 119 87 
patients, negative in 78; in the remaining cases, the level of expression was unknown. About half of the 88 
patients had PS 1, 37.2% had PS 0 and 12.1% had PS 2 at the first administration of ICI. More than 2 sites of 89 
distant disease were documented in 166 patients at the beginning of IO. Two hundred five pts received an 90 
anti-PD1, 77 an anti-PDL1, 8 an anti-CTLA4 or a combo-IO. ICIs were globally well tolerated, as less than one 91 
third of patients developed a toxicity graded ≥2. Most clinical and pathological characteristics were 92 
uniformly distributed across age classes, except for gender and histology. In particular, a higher prevalence 93 
of male gender and squamous histology was observed in the intermediate age group (70-79 year-old 94 
patients). Patient and treatment characteristics are detailed in Table 1. 95 
When stratifying the global population according to age, no toxicity concerns emerged even among the 96 
eldest patients. In particular, the incidence of adverse events graded ≥2 was comparable across age groups 97 
(35.8% vs 32.7% vs 37.5% for pts aged<70 vs 70-79 vs ≥80 year-old, p 0.6493).  98 
As regards IO efficacy, no differences in Response Rate (RR) emerged between the three classes (21.5% vs 99 
22.3% vs 18.8% for pts aged<70 vs 70-79 vs ≥80 yo, respectively; p 0.9470). Median PFS of the global 100 
population was 3.0 months (95%CI 2.57-3.75); median OS was 9.93 months (95%CI 8.26-12-11). Considering 101 
age as a continuous variable, the impact of this factor on both PFS and OS was not significant (p 0.1263 and 102 
p 0.7077, respectively). Consistently with this finding, the three classes of patients did not show 103 
significantly different outcome, median PFS being 2.8 months for patients aged <70, 3.5 months for 104 
patients aged 70-79, 2.6 months for patients aged ≥80 (p 0.2020). Corresponding median OS was 9.1 105 
months for patients aged <70, 11.3 months for patients aged 70-79, 9.6 months for patients aged ≥80 (p 106 
0.5154). Results were comparable after stratification for gender (p 0.516 for PFS, p 0.5154 for OS) and 107 
histology (p 0.9057 for PFS, p 0.1002 for OS), which were the variables showing an imbalance among age 108 
classes. Kaplan-Meier curves for PFS and OS according to age classes are reported in Figure 1 and 2. 109 
At univariate analysis, the variables showing an impact on survival were PD-L1 status (p 0.0026 for PFS, p 110 
0.0242 for OS), ECOG PS (p<0.0001 for PFS and OS), number of metastatic sites (p 0.0019 for PFS, p 0.0006 111 
for OS) and IO line (p<0.0001 for PFS, 0.0006 for OS). Multivariate analysis confirmed an independent role 112 
on PFS for ECOG PS and IO line, on OS for ECOG PS and number of metastatic sites. Results of univariate 113 
and multivariate analyses are reported in Table 2 and 3. 114 
Discussion 115 
Pre-clinical data have shown that aging can induce measurable changes in some functions of systemic 116 
immunity.  In particular a progressive and global remodelling of immune functions during aging involving 117 
both innate and adaptive immunity, known as immunosenescence, may potentially predict benefit from IO 118 
in NSCLC patients [4].  Mice experiments have also proved that elderly animals have a reduced variability of 119 
T cell populations, a slower lymphocyte proliferation after antigen stimulation and a reduced cytokine 120 
secretion [5]. Furthermore, after exposure to IO, elderly mice have an increased risk of severe immune-121 
related adverse events than young controls, due to uncontrolled release of pro-inflammatory mediators [6]. 122 
Nonetheless, data on cancer patients are less clear. Therefore, some reviews and meta-analyses have been 123 
performed with the purpose of pooling data from clinical trials. Such works have generally focused on 124 
different tumors (NSCLC, urothelial carcinoma, prostate cancer, melanoma) and compounds (nivolumab, 125 
pembrolizumab, combined IO). Their results have been concordant in showing a PFS benefit also for elderly 126 
patients treated with IO, while there was a trend towards a higher Hazard Ratio (HR) in OS as compared to 127 
younger patients, in particular for nivolumab and for NSCLC. No data have supported the suspicion of an 128 
increased incidence of toxicity among elderly patients [7].  129 
 A recent work have addressed the topic of IO in the elderly in the real-world, analyzing a cohort of 130 
squamous NSCLC patients enrolled in Italian nivolumab expanded access program. The authors have 131 
divided the patients into three groups: <65, 65-75 and >75 year-old. No differences in RR and PFS could be 132 
observed among the classes, while OS was shorter for the eldest patients as a likely consequence of 133 
comorbidities leading to death from other causes. IO was well tolerated across all age groups. The authors 134 
concluded that nivolumab appears as a safe and effective second line treatment for elderly patients with 135 
squamous NSCLC in a real-life setting [8]. 136 
Furthermore, a pooled analysis of three studies comparing pembrolizumab to chemotherapy (Keynote 024, 137 
Keynote 042 and Keynote 010) has been recently presented. Data about almost 400 NSCLC patients aged 138 
>75  have shown that IO improved OS also in the eldest cohort of the trials, irrespective of line of therapy 139 
and PD-L1 cutoff (>1% vs >50%). Elderly patients treated with IO experienced less adverse events than 140 
those receiving chemotherapy; toxicity of pembrolizumab was similar to that reported in the younger 141 
cohort of the trials [9]. 142 
In our case series, we chose to stratify the patients using different age cutoffs. Our purpose was to evaluate 143 
safety and efficacy of IO in a cohort of patients with a considerably  older age than that included in most 144 
trials. Although the group of the eldest patients was quite small, we could not evidence any difference in 145 
RR, PFS and even OS. A numeric trend towards a longer survival of the intermediate class was observed, but 146 
it was likely an effect of the small number of cases in each group. However, these slight differences were 147 
not significant. Indeed, the performance of IO was fair also for patients aged ≥80, with results that are 148 
comparable to those reported in clinical trials. Notably, a safe toxicity profile was confirmed in our case 149 
series across all age groups. This result is particularly relevant considering that literature data are scarce for 150 
patients aged ≥75 and even ≥80. A report of four patients aged >90 treated successfully and safely with IO 151 
have been recently published, but, at the best of our knowledge, this is the largest case series of NSCLC 152 
patients aged ≥80 treated with ICIs [10].  153 
This study presents some limitation. First of all, the only estimate of patients’ global functioning we could 154 
evaluate was ECOG performance status. Patients were not evaluated through a comprehensive geriatric 155 
characterization and no standardized geriatric scales were applied. This surely impairs the possibility of 156 
generalize data and compare them with other case series from different Institutions. Secondarily, the 157 
retrospective nature of the analysis may have implied an under-report of adverse events and reduced the 158 
reliability of toxicity grading. 159 
Given such limitation, however, this single Institution experience confirms a satisfactory safety and toxicity 160 
profile of IO in elderly patients. On the contrary, a poor PS appears as a strong negative predictive and 161 
prognostic factor during treatment with ICIs. This underlines the importance of considering PS, instead of 162 
age, when evaluating  patients potentially candidate to IO. Therefore, a comprehensive evaluation of each 163 
cancer patient in advanced age, with the cooperation of a specialist in geriatric medicine, considering the 164 
whole medical picture and the global functioning besides the age, should be performed when deciding if a 165 
patient is candidate or not to receive active treatment.  166 
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A total of 290 cases were identified, with a median age of 67 (range: 29-89). One hundred eighty patients 85 
were aged <70, 94 were aged 70-79, 16 were aged ≥80. In the global population there was a slight 86 
prevalence of male gender (61.7%), and most patients were current or former smoker at the beginning of 87 
IO (80.7%). Tumor histology was non-squamous in 77.6% of cases. PD-L1 was classified as positive in 119 88 
patients, negative in 78; in the remaining cases, the level of expression was unknown. About half of the 89 
patients had PS 1, 37.2% had PS 0 and 12.1% had PS 2 at the first administration of ICI. More than 2 sites of 90 
distant disease were documented in 166 patients at the beginning of IO. Two hundred five pts received an 91 
anti-PD1, 77 an anti-PDL1, 8 an anti-CTLA4 or a combo-IO. ICIs were globally well tolerated, as less than one 92 
third of patients developed a toxicity graded ≥2. Most clinical and pathological characteristics were 93 
uniformly distributed across age classes, except for gender and histology. In particular, a higher prevalence 94 
of male gender and squamous histology was observed in the intermediate age group (70-79 year-old 95 
patients). Patient and treatment characteristics are detailed in Table 1. 96 
When stratifying the global population according to age, no toxicity concerns emerged even among the 97 
eldest patients. In particular, the incidence of adverse events graded ≥2 was comparable across age groups 98 
(35.8% vs 32.7% vs 37.5% for pts aged<70 vs 70-79 vs ≥80 year-old, p 0.6493).  99 
As regards IO efficacy, no differences in Response Rate (RR) emerged between the three classes (21.5% vs 100 
22.3% vs 18.8% for pts aged<70 vs 70-79 vs ≥80 yo, respectively; p 0.9470). Median PFS of the global 101 
population was 3.0 months (95%CI 2.57-3.75); median OS was 9.93 months (95%CI 8.26-12-11). Considering 102 
age as a continuous variable, the impact of this factor on both PFS and OS was not significant (p 0.1263 and 103 
p 0.7077, respectively). Consistently with this finding, the three classes of patients did not show 104 
significantly different outcome, median PFS being 2.8 months for patients aged <70, 3.5 months for 105 
patients aged 70-79, 2.6 months for patients aged ≥80 (p 0.2020). Corresponding median OS was 9.1 106 
months for patients aged <70, 11.3 months for patients aged 70-79, 9.6 months for patients aged ≥80 (p 107 
0.5154). Results were comparable after stratification for gender (p 0.516 for PFS, p 0.5154 for OS) and 108 
histology (p 0.9057 for PFS, p 0.1002 for OS), which were the variables showing an imbalance among age 109 
classes. Kaplan-Meier curves for PFS and OS according to age classes are reported in Figure 1 and 2. 110 
At univariate analysis, the variables showing an impact on survival were PD-L1 status (p 0.0026 for PFS, p 111 
0.0242 for OS), ECOG PS (p<0.0001 for PFS and OS), number of metastatic sites (p 0.0019 for PFS, p 0.0006 112 
for OS) and IO line (p<0.0001 for PFS, 0.0006 for OS). Multivariate analysis confirmed an independent role 113 
on PFS for ECOG PS and IO line, on OS for ECOG PS and number of metastatic sites. Results of univariate 114 
and multivariate analyses are reported in Table 2 and 3. 115 
Discussion 116 
Pre-clinical data have shown that aging can induce measurable changes in some functions of systemic 117 
immunity.  In particular a progressive and global remodelling of immune functions during aging involving 118 
both innate and adaptive immunity, known as immunosenescence, may potentially predict benefit from IO 119 
in NSCLC patients [4].  Mice experiments have also proved that elderly animals have a reduced variability of 120 
T cell populations, a slower lymphocyte proliferation after antigen stimulation and a reduced cytokine 121 
secretion [5]. Furthermore, after exposure to IO, elderly mice have an increased risk of severe immune-122 
related adverse events than young controls, due to uncontrolled release of pro-inflammatory mediators [6]. 123 
Nonetheless, data on cancer patients are less clear. Therefore, some reviews and meta-analyses have been 124 
performed with the purpose of pooling data from clinical trials. Such works have generally focused on 125 
different tumors (NSCLC, urothelial carcinoma, prostate cancer, melanoma) and compounds (nivolumab, 126 
pembrolizumab, combined IO). Their results have been concordant in showing a PFS benefit also for elderly 127 
patients treated with IO, while there was a trend towards a higher Hazard Ratio (HR) in OS as compared to 128 
younger patients, in particular for nivolumab and for NSCLC. No data have supported the suspicion of an 129 
increased incidence of toxicity among elderly patients [7].  130 
 A recent work have addressed the topic of IO in the elderly in the real-world, analyzing a cohort of 131 
squamous NSCLC patients enrolled in Italian nivolumab expanded access program. The authors have 132 
divided the patients into three groups: <65, 65-75 and >75 year-old. No differences in RR and PFS could be 133 
observed among the classes, while OS was shorter for the eldest patients as a likely consequence of 134 
comorbidities leading to death from other causes. IO was well tolerated across all age groups. The authors 135 
concluded that nivolumab appears as a safe and effective second line treatment for elderly patients with 136 
squamous NSCLC in a real-life setting [8]. 137 
Furthermore, a pooled analysis of three studies comparing pembrolizumab to chemotherapy (Keynote 024, 138 
Keynote 042 and Keynote 010) has been recently presented. Data about almost 400 NSCLC patients aged 139 
>75  have shown that IO improved OS also in the eldest cohort of the trials, irrespective of line of therapy 140 
and PD-L1 cutoff (>1% vs >50%). Elderly patients treated with IO experienced less adverse events than 141 
those receiving chemotherapy; toxicity of pembrolizumab was similar to that reported in the younger 142 
cohort of the trials [9]. 143 
In our case series, we chose to stratify the patients using different age cutoffs. Our purpose was to evaluate 144 
safety and efficacy of IO in a cohort of patients with a considerably  older age than that included in most 145 
trials. Although the group of the eldest patients was quite small, we could not evidence any difference in 146 
RR, PFS and even OS. A numeric trend towards a longer survival of the intermediate class was observed, but 147 
it was likely an effect of the small number of cases in each group. However, these slight differences were 148 
not significant. Indeed, the performance of IO was fair also for patients aged ≥80, with results that are 149 
comparable to those reported in clinical trials. Notably, a safe toxicity profile was confirmed in our case 150 
series across all age groups. This result is particularly relevant considering that literature data are scarce for 151 
patients aged ≥75 and even ≥80. A report of four patients aged >90 treated successfully and safely with IO 152 
have been recently published, but, at the best of our knowledge, this is the largest case series of NSCLC 153 
patients aged ≥80 treated with ICIs [10].  154 
This study presents some limitation. First of all, the only estimate of patients’ global functioning we could 155 
evaluate was ECOG performance status. Patients were not evaluated through a comprehensive geriatric 156 
characterization and no standardized geriatric scales were applied. This surely impairs the possibility of 157 
generalize data and compare them with other case series from different Institutions. Secondarily, the 158 
retrospective nature of the analysis may have implied an under-report of adverse events and reduced the 159 
reliability of toxicity grading. 160 
Given such limitation, however, this single Institution experience confirms a satisfactory safety and toxicity 161 
profile of IO in elderly patients. On the contrary, a poor PS appears as a strong negative predictive and 162 
prognostic factor during treatment with ICIs. This underlines the importance of considering PS, instead of 163 
age, when evaluating  patients potentially candidate to IO. Considering that elderly patients commonly 164 
present comorbidities that can contra-indicate the prescription of chemotherapy or increase the risk of 165 
severe toxicity with cytotoxic treatment, IO could often become the only applicable treatment option for 166 
these cases. Therefore, a comprehensive evaluation of each cancer patient in advanced age, with the 167 
cooperation of a specialist in geriatric medicine, considering the whole medical picture and the global 168 
functioning besides the age, should be performed when deciding if a patient is candidate or not to receive 169 
active treatment.  170 
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Tables 
Table 1. Patient and treatment characteristics with Chi square test. 
 Age <70, N1 (%) Age 70-79, N1 (%) Age ≥80, N1 (%) Total 
Gender     
Male 102 (56.7) 63 (67.0) 14 (87.5) 179 (61.7) 
Female 78 (43.3) 31 (33.0) 2 (12.5) 111 (38.3) 
 p 0.0228  
Smoking status     
Current/former smoker 144 (80.0) 78 (83.0) 12 (75.0) 234 (80.7) 
Never smoker 36 (20.0) 16 (17.0) 4 (25.0) 56 (19.3) 
 p 0.4879  
Histology     
Squamous NSCLC2 31 (17.2) 32 (34.0) 2 (12.5) 65 (22.4) 
Non-squamous NSCLC2 149 (82.8) 62 (66.0) 14 (87.5) 225 (77.6) 
  p 0.0071   
PD-L1 status     
Positive 69 (38.4) 43 (45.7) 7 (43.8) 119 (41.0) 
Negative 58 (32.2) 16 (17.0) 4 (25.0) 78 (26.9) 
Unknown 53 (29.4) 35 (37.3) 5 (31.2) 93 (32.1) 
 NA  
PS3 ECOG     
0 74 (41.1) 32 (34.0) 2 (12.5) 108 (37.2) 
1 88 (48.9) 47 (50.0) 12 (75.0) 147 (50.7) 
2 18 (10.0) 15 (16.0) 2 (12.5) 35 (12.1) 
 p 0.1153  
N1 of metastatic sites     
1 74 (41.1) 44 (46.8) 6 (37.5) 124 (42.8) 
Tables
≥2 106 (58.9) 50 (53.2) 10 (62.5) 166 (57.2) 
 p 0.6034  
ICI4 class     
Anti-PD1 120 (66.7) 72 (76.6) 13 (81.3) 205 (70.7) 
Anti-PDL1 53 (29.4) 21 (22.3) 3 (18.8) 77 (26.5) 
Combo-IO5 or other 7 (3.9) 1 (1.1) 0 (0) 8 (2.8) 
 p 0.1459  
Toxicity graded ≥2     
Yes 48 (26.7) 26 (27.7) 6 (37.5) 80 (27.6) 
No 132 (73.3) 68 (72.3) 10 (62.5) 210 (72.4) 
 p 0.8636  
Total 180 (62.1) 94 (32.4) 16 (5.5) 290 (100) 
 
 Table 2. Univariate and multivariate analysis for PFS and OS. 
 PFS6 (months) OS7 (months) 
 Median 95%CI p value Median 95%CI p value 
Gender    
0.5168 
   
0.5154 Male 2.93 2.43 3.75 9.57 6.97 12.10 
Female 2.99 2.34 5.13 9.93 7.83 15.17 
Smoking status    
0.4254 
   
0.6830 Never smoker 2.99 1.91 5.49 11.32 5.07 20.69 
Current/former smoker 3.16 2.57 3.82 10.23 8.26 13.39 
IO5 agent    
0.0631 
   
0.4688 
Anti-PD1 2.99 2.57 3.82 9.08 7.43 11.32 
Anti-PDL1 3.31 2.01 5.62 11.25 7.53 17.76 
Anti-CTLA4 or combo-
IO5 
2.16 1.25 3.56 14.21 3.16 24.18 
Histology    
0.9429 
   
0.1053 Squamous NSCLC2 3.19 2.34 4.64 7.83 5.23 11.32 
Non-squamous NSCLC2 2.90 2.43 3.82 10.26 8.29 13.49 
PD-L1 status    
0.0026 
   
0.0242 
Positive 4.44 3.13 6.65 9.08 5.92 13.22 
Negative 2.57 1.91 3.72  13.52 9.57 24.44  
 HR 95%CI p value HR 95%CI p value 
 0.754 0.526 1.054 0.0964 0.727 0.489 1.078  0.1128 
PS3 ECOG    
<0.0001 
   
<0.0001 
0 5.49 3.75 7.83 21.91 13.39 24.44 
1 2.63 2.17 3.26 7.57 5.13 10.26 
≥2 1.88 1.45 2.60 2.67 1.52 5.13 
 HR 95%CI p value HR 95%CI p value 
 1.610 1.236 2.097 0.0004 2.347 1.705 3.231 <0.0001 
N1 of metastatic sites    
0.0019 
   
0.0006 1 3.82 2.99 5.13 13.39 9.64 21.91 
≥2 2.57 2.10 2.83 7.76 5.43 10.23 
 HR 95%CI p value HR 95%CI p value 
 1.337 0.950 1.882 0.0959 1.689 1.136 2.539 0.0098 
Line of IO5    
<0.0001 
   
0.0006 
1 6.81 4.18 11.25 22.01 12.11 NR 
2 2.63 2.30 3.26 7.76 5.43 9.93 
≥3 1.92 1.84 2.99 8.59 5.23 13.39 
 HR 95%CI p value HR 95%CI p value 
 1.345 1.084 1.669 0.0070 1.151 0.888 1.492 0.2890 
Table legend 
1 Number 
2 Non-Small Cell Lung Cancer 
3 Performance Status 
4 Immune Checkpoint Inhibitor 
5 Immunotherapy 
6 Progression Free Survival 
7 Overall Survival 
 
